Floatz logo

Busulphan

Amyloidosis

Herbert Irving Comprehensive Cancer CenterPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB
Cyclophosphamide
University of Alabama at Birmingham
Phase 2BB
FILGRASTIM
Memorial Sloan Kettering Cancer Center
Phase 2BB
EVUZAMITIDE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2BB

View all 29 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →